Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maarten J Ijzerman

Showing results (1-10 of 210) with videos related to

Pageof 21
Sort By:
The Lancet. Gastroenterology & Hepatology|July 30, 2021
Cost of colorectal cancer care: sufficient to inform cancer policy?Maarten J IJzerman
Expert Review of Pharmacoeconomics & Outcomes Research|April 28, 2016
Are current ICER thresholds outdated? Valuing medicines in the era of personalized healthcarePricivel Carrera, Maarten J IJzerman
Archives of Physical Medicine and Rehabilitation|December 11, 2002
Feasibility of the physiological cost index as an outcome measure for the assessment of energy expenditure during walkingMaarten J Ijzerman, Anand V Nene
Ecancermedicalscience|September 29, 2017
Responsible pricing in value-based assessment of cancer drugs: real-world data are an inevitable addition to select meaningful new cancer treatmentsWim van Harten, Maarten J IJzerman
Clinical Rehabilitation|June 8, 2004
Percutaneous neuromuscular electrical stimulation (P-NMES) for treating shoulder pain in chronic hemiplegia. Effects on shoulder pain and quality of lifeGerbert J Renzenbrink, Maarten J IJzerman
Applied Health Economics and Health Policy|August 31, 2011
Early assessment of medical technologies to inform product development and market access: a review of methods and applicationsMaarten J Ijzerman, Lotte M G Steuten
Expert Review of Pharmacoeconomics & Outcomes Research|December 17, 2016
A systematic review and checklist presenting the main challenges for health economic modeling in personalized medicine: towards implementing patient-level modelsKoen Degeling, Hendrik Koffijberg, Maarten J IJzerman
Pharmacoeconomics|November 30, 2013
Why should regulators consider using patient preferences in benefit-risk assessment?Janine A van Til, Maarten J Ijzerman
Clinical Rehabilitation|August 6, 2008
Electrical stimulation of the upper extremity in stroke: cyclic versus EMG-triggered stimulationJoke R de Kroon, Maarten J IJzerman
Discover Oncology|September 24, 2025
Implementation of whole genome sequencing in cancer management: modelling and sensitivity analysis using system dynamicsHadi Akbarzadeh Khorshidi, Marzieh Soltanolkottabi, Maarten J IJzerman
Pageof 21

Showing results (1-10 of 210) with videos related to

Sort By:
Pageof 21
The Lancet. Gastroenterology & Hepatology|July 30, 2021
Cost of colorectal cancer care: sufficient to inform cancer policy?Maarten J IJzerman
Expert Review of Pharmacoeconomics & Outcomes Research|April 28, 2016
Are current ICER thresholds outdated? Valuing medicines in the era of personalized healthcarePricivel Carrera, Maarten J IJzerman
Archives of Physical Medicine and Rehabilitation|December 11, 2002
Feasibility of the physiological cost index as an outcome measure for the assessment of energy expenditure during walkingMaarten J Ijzerman, Anand V Nene
Ecancermedicalscience|September 29, 2017
Responsible pricing in value-based assessment of cancer drugs: real-world data are an inevitable addition to select meaningful new cancer treatmentsWim van Harten, Maarten J IJzerman
Clinical Rehabilitation|June 8, 2004
Percutaneous neuromuscular electrical stimulation (P-NMES) for treating shoulder pain in chronic hemiplegia. Effects on shoulder pain and quality of lifeGerbert J Renzenbrink, Maarten J IJzerman
Applied Health Economics and Health Policy|August 31, 2011
Early assessment of medical technologies to inform product development and market access: a review of methods and applicationsMaarten J Ijzerman, Lotte M G Steuten
Expert Review of Pharmacoeconomics & Outcomes Research|December 17, 2016
A systematic review and checklist presenting the main challenges for health economic modeling in personalized medicine: towards implementing patient-level modelsKoen Degeling, Hendrik Koffijberg, Maarten J IJzerman
Pharmacoeconomics|November 30, 2013
Why should regulators consider using patient preferences in benefit-risk assessment?Janine A van Til, Maarten J Ijzerman
Clinical Rehabilitation|August 6, 2008
Electrical stimulation of the upper extremity in stroke: cyclic versus EMG-triggered stimulationJoke R de Kroon, Maarten J IJzerman
Discover Oncology|September 24, 2025
Implementation of whole genome sequencing in cancer management: modelling and sensitivity analysis using system dynamicsHadi Akbarzadeh Khorshidi, Marzieh Soltanolkottabi, Maarten J IJzerman
Pageof 21